TY - JOUR
TI - Delayed breast cellulitis following surgery for breast cancer: A literature review
AU - Exarchos, G.
AU - Metaxa, L.
AU - Constantinidou, A.
AU - Kontos, M.
JO - Breast Care
PY - 2019
VL - 14
TODO - 1
SP - 48-52
PB - S Karger AG
SN - 1661-3791, 1661-3805
TODO - 10.1159/000494691
TODO - hyaluronic acid, angiosarcoma;  antibiotic therapy;  bacterial growth;  breast cancer;  breast tenderness;  cancer recurrence;  cell proliferation;  cellulitis;  clinical outcome;  debridement;  desquamation;  differential diagnosis;  edema;  erythema;  female;  fever;  fibrosis;  fine needle aspiration biopsy;  heat;  human;  Hunter syndrome;  hypothyroidism;  inflammation;  leukocytosis;  lymphadenopathy;  lymphedema;  Marfan syndrome;  mastectomy;  metastasis;  nuclear magnetic resonance imaging;  obesity;  osteogenesis imperfecta;  partial mastectomy;  pathophysiology;  postoperative infection;  priority journal;  Review;  risk factor;  Staphylococcus aureus
TODO - Background: Delayed breast cellulitis (DBC) is a relatively rare complication following breast-conserving surgery. It is often challenging to distinguish DBC from other clinical conditions such as postoperative infection, inflammatory reaction following radiation, and recurrent inflammatory carcinoma. The definition of DBC, diagnostic approach, and treatment are not well established in the literature. Methods: We performed a literature search with the keywords 'Delayed breast cellulitis' and 'Breast conservation therapy cellulitis', without limitations to the dates or the article types, in the PubMed database. Information about the number of cases with DBC, the age of the patients, the interval between the onset of symptoms and the time of surgery or radiotherapy, and the type and outcome of DBC treatment were reviewed and tabulated. Results: We identified only 5 papers that were absolutely related to our subject, reflecting the fact that 'delayed breast cellulitis' is a fairly unknown term and the condition is rather underreported. Although most agree that DBC is primarily an aseptic inflammatory process, bacterial growth may contribute to its development or recurrence. Obesity, breast size, location of the breast tumor, removal of the axillary lymph nodes, and connective tissue disorders are considered as risk factors. There is no clear evidence on how DBC should be best managed. Antibiotic treatment is controversial, and many authors suggest anti-inflammatory agents or sole observation. Prevention of lymph stasis and its consequences with massage and skin care may be helpful. Despite the fact that malignancy is rare, in cases where the condition persists for more than 4 months, a core biopsy should be performed to rule out recurrent or second primary carcinoma. Conclusion: The correct diagnostic approach is essential as it provides patients with reassurance, minimizes anxiety, and prevents unnecessary medical investigations, treatments, and costs. © 2018 S. Karger GmbH, Freiburg. All rights reserved.
ER -